Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Other financing activities (2020 - 2025)

Insight Molecular Diagnostics' Other financing activities history spans 4 years, with the latest figure at $487000.0 for Q1 2025.

  • For Q1 2025, Other financing activities changed N/A year-over-year to $487000.0; the TTM value through Sep 2025 reached $1.3 million, up 145.91%, while the annual FY2024 figure was $1.4 million, 221.78% up from the prior year.
  • Other financing activities for Q1 2025 was $487000.0 at Insight Molecular Diagnostics, down from $836000.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $2.7 million in Q1 2021 and bottomed at -$1000.0 in Q4 2021.
  • The 3-year median for Other financing activities is $538000.0 (2024), against an average of $907200.0.
  • The largest YoY upside for Other financing activities was 267500.0% in 2021 against a maximum downside of 267500.0% in 2021.
  • A 3-year view of Other financing activities shows it stood at -$1000.0 in 2021, then soared by 83700.0% to $836000.0 in 2024, then plummeted by 41.75% to $487000.0 in 2025.
  • Per Business Quant, the three most recent readings for IMDX's Other financing activities are $487000.0 (Q1 2025), $836000.0 (Q4 2024), and $538000.0 (Q2 2024).